April 04, 2013
1 min read
Save

Treatment of pediatric obesity with guided self-help shows promise

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Guided self-help treatment programs for pediatric obesity may help decrease children’s BMI, new research suggests.

The study included 50 overweight or obese children aged 8 to 12 years who were assigned to immediate treatment or delayed treatment. Participants were part of a guided self-help treatment of pediatric obesity for 12 visits during 5 months.

Participants assigned to immediate treatment started the guided self-help treatment after the baseline (T1), attended post-treatment (T2) and 6-month post-treatment (T3) assessments. Participants assigned to delayed treatment attended baseline treatment (T1), attended another assessment after 5 months (T2), attended post-treatment assessments at the completion of the self-help (T3) and a 6-month post-treatment assessment (T4).

Of the immediate treatment group, 64% were obese at baseline and 68% of participants in the delayed treatment group were obese.

Researchers found that children in the immediate treatment group decreased their BMI significantly more than the delayed treatment group (P<.001). They also found similar results for BMI z score and percentage overweight.

At the 6-month mark, changes were maintained for BMI zscore (P<.001) and percentage overweight (P<.05) but not BMI.

“Importantly, the initial results of this study showed that a self-help program, guided by professionals, may be as effective in helping kids to lose weight as a traditional, clinic-based weight loss program,” Kerri Boutelle, PhD, associate professor of pediatrics and psychiatry at UC San Diego School of Medicine, said in a press release.

Disclosure: One researcher reports receiving research grants from Alkermes, Novartis and Shire.